These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26536664)

  • 1. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
    ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
    Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
    Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
    Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
    Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
    Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
    Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
    J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
    J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
    Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
    MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
    England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
    Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
    Kobayashi K; Sasaki T; Takenaka F; Yakushiji H; Fujii Y; Kishi Y; Kita S; Shen L; Kumon H; Matsuura E
    J Immunol Res; 2015; 2015():268172. PubMed ID: 25883990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
    Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
    J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
    Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
    Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
    Alsaid H; Skedzielewski T; Rambo MV; Hunsinger K; Hoang B; Fieles W; Long ER; Tunstead J; Vugts DJ; Cleveland M; Clarke N; Matheny C; Jucker BM
    PLoS One; 2017; 12(4):e0176075. PubMed ID: 28448604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.